Anti-PD1 antibody
Specifications
| Product type: | Primary antibody |
| Antigen: | PD1 |
| Immunogen: | Recombinant protein |
| Species immunized: | Mouse |
| Isotype: | IgG |
| Applications: | Western Blot (1:600-1:2100); Immunocytochemistry (1:100-1:250); Immunohistochemistry (1:150-1:550); Flow Cytometry (1:100-1:150) |
| Reactivity: | Human, Mouse |
| Clonality (clone number): | Monoclonal |
| Form: | Liquid |
| Buffer: | 1*TBS (pH7.4), 1%BSA, 40%Glycerol. Preservative: 0.05% Sodium Azide. |
| Concentration: | 1mg/ml |
| Purity: | Protein A affinity purified |
| Storage: | Aliquot and freeze at -20℃. Avoid multiple freeze/thaw cycles. |
| Alternative names: | CD279 antibody |
| CD279 antigen antibody | |
| hPD 1 antibody | |
| hPD l antibody | |
| hPD-1 antibody | |
| hSLE1 antibody | |
| PD 1 antibody | |
| PD-1 antibody | |
| PD1 antibody | |
| PDCD 1 antibody | |
| PDCD1 antibody | |
| PDCD1_HUMAN antibody | |
| Programmed cell death 1 antibody | |
| Programmed cell death 1 protein antibody | |
| Programmed cell death protein 1 antibody | |
| Protein PD 1 antibody | |
| Protein PD-1 antibody | |
| SLEB2 antibody | |
| Systemic lupus erythematosus susceptibility 2 antibody |
Target information
Inhibitory receptor on antigen activated T-cells that plays a critical role in induction and maintenance of immune tolerance to self (PubMed:10485649, PubMed:11698646, PubMed:11209085, PubMed:21300912). Delivers inhibitory signals upon binding to ligands, such as CD274/PDCD1L1 and CD273/PDCD1LG2 (PubMed:11015443, PubMed:11224527, PubMed:22641383, PubMed:18287011, PubMed:18641123). Following T-cell receptor (TCR) engagement, PDCD1 associates with CD3-TCR in the immunological synapse and directly inhibits T-cell activation (PubMed:22641383). Suppresses T-cell activation through the recruitment of PTPN11/SHP-2: following ligand-binding, PDCD1 is phosphorylated within the ITSM motif, leading to the recruitment of the protein tyrosine phosphatase PTPN11/SHP-2 that mediates dephosphorylation of key TCR proximal signaling molecules, such as ZAP70, PRKCQ/PKCtheta and CD247/CD3zeta (PubMed:11698646, PubMed:22641383). The PDCD1-mediated inhibitory pathway is exploited by tumors to attenuate anti-tumor immunity and facilitate tumor survival (By similarity).
Provider
Erpantech Laboratory
